Human Acellular Vessel not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.”In the company’s words, NCT03183245 on ClinicalTrials.gov
- Tested for
- Renal Failure (2 trials), End Stage Renal Disease (2 trials), Hemodialysis (2 trials), Vascular Access (2 trials), Peripheral Artery Disease
- Main trialPhase 3
- “The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.”In the company’s words, NCT02644941 on ClinicalTrials.gov
Other drugs for Renal Failure
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | May 2019 | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis | |
| Phase 3Completed | 22 Apr 2024 | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis | |
| Phase 2Completed | Dec 2020 | Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026